Page last updated: 2024-12-08
wy 41770
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Wy 41770: produced no gastric irritation in rats; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 165241 |
| SCHEMBL ID | 677773 |
| MeSH ID | M0124928 |
Synonyms (14)
| Synonym |
|---|
| 5h-dibenzo[a,d][7]annulen-5-ylideneacetic acid |
| wy-41770 |
| wy 41770 |
| 4517-99-1 |
| (5h-dibenzo(a,d)cyclohepten-5-ylidene)acetic acid |
| wy-41,770 |
| acetic acid, 5h-dibenzo(a,d)cyclohepten-5-ylidene- |
| SCHEMBL677773 |
| 5h-dibenzo[a,d][7]annulen-5-ylidenacetic acid |
| (5h dibenzo[a,d]cyclohepten-5-ylidene)acetic acid |
| POBFODAHUPCAAG-UHFFFAOYSA-N |
| (5h-dibenzo[a,d]cyclohepten-5-ylidene)acetic acid |
| DTXSID70196409 |
| (5h-dibenzo[a,d]-cyclohepten-5-ylidene) acetic acid |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The drug was rapidly and well absorbed in all four animal species." | ( Disposition of (5H-dibenzo [a,d]cyclohepten-5-ylidene)acetic acid in laboratory animals. Schillings, RT; Sisenwine, SF, ) | 0.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Wy-41,770 induced superficial erosions only in the cecum 26 hr after a single oral dose of 250 or 500 mg/kg of the drug, progressing to ulcers after 5 days dosing with ultrastructural evidence of bacteria in the mucosa." | ( Mucosal lesions induced in the rat intestinal tract by the anti-inflammatory drug, Wy-41,770, a weak inhibitor of prostaglandin synthesis, contrasted with those from the potent prostaglandin inhibitor, indomethacin. Rainsford, KD, 1988) | 0.27 |
| " when dosed before sensitization." | ( Immunomodulating activity of Wy-41,770 (5H-dibenzo[A,D]cyclohepten-5-ylidene) acetic acid. Carlson, RP; Datko, LJ; Lewis, AJ; O'Neill-Davis, L, 1986) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||